2017

Request for Proposals: HSCI Seed Grant Program 2017

March 21, 2017

Harvard Stem Cell Institute (HSCI) invites applications for seed grant funding for its 2017 cycle. The purpose of this program is to provide funding for innovative projects in the field of stem cell and regenerative biology. As was the case last year, HSCI strongly encourages proposals with a translational focus, or which are otherwise poised to accelerate the development of new stem cell-based therapies or cures. However, proposals at all stages of development are welcome. HSCI intends to award up to ten grants in response to this request for proposals, contingent upon the number and...

Read more about Request for Proposals: HSCI Seed Grant Program 2017

Helping beta cells divide

March 17, 2017

 

Scientists identify a key barrier to proliferation of inuslin-producing cells

If you become resistant to insulin, a condition that is a precursor to type 2 diabetes, your body tries to compensate by producing more of the “beta” cells in the pancreas that produce the critical hormone. Researchers have long sought to understand why these cells often fail to proliferate in people who go on to develop the disease. Studying both humans and mice, scientists at Joslin Diabetes Center now have pinpointed one key biological mechanism that can prevent...

Read more about Helping beta cells divide
Scott Armstrong MD PhD photo

Scott Armstrong, MD, PhD

Dana-Farber Cancer Institute
Boston Children's Hospital
Harvard Medical School | Broad Institute of MIT and Harvard

The Armstrong laboratory is focused on the mechanisms of cancer development with a focus on leukemia. One major interest in the lab is the relationship between leukemia, normal hematopoietic stem cells and the various hematopoietic cells of origin of leukemia. The lab is also studying the role of histone modifications and chromosome ... Read more about Scott Armstrong, MD, PhD

Amy Wagers, PhD

Amy Wagers, PhD

Co-chair, Harvard Department of Stem Cell and Regenerative Biology
Senior Investigator, Islet Cell and Regenerative Biology, Joslin Diabetes Center

Stem cells are rare and unique cells capable of generating many different types of cells needed in the body. In adult tissues, different organs contain different stem cell populations, each of which produces a subset of the body's cells. For example, hematopoietic (blood-forming) stem cells generate all of the red and white blood cells needed to deliver oxygen to body tissues, fight infection, and stop bleeding. Similarly, myogenic (muscle-forming) stem cells generate mature muscle fibers necessary for controlled contraction of skeletal muscle. Work in the Wagers Lab focuses on understanding the mechanisms that regulate the function of these blood-forming and muscle-forming stem cells so that their potential can be optimally exploited for the treatment of diseases such as cancer, anemia, muscular dystrophy, and diabetes.... Read more about Amy Wagers, PhD

Khalid Shah, MS, PhD

Khalid Shah, MS, PhD

Vice Chair of Research, Brigham and Women's Hospital
Director, Center for Stem Cell Therapeutics and Imaging, Harvard Medical School

Successful treatment of brain tumors remains one of the greatest challenges in oncology. The recognition that different stem cell types, including neural stem cells (NSCs) can integrate appropriately throughout the mammalian brain following transplantation has unveiled new possibilities for their use in neural transplantation. Our laboratory has shown that different stem cell types home to sites of cerebral pathology and thus can be armed with therapeutic transgenes, a strategy that can be used to inhibit tumor growth by targeting angiogenesis or selectively inducing apoptosis in proliferating tumor cells in the brain.... Read more about Khalid Shah, MS, PhD

Sridhar Ramaswamy, MD

Sridhar Ramaswamy, MD

Senior VP for Research and Development, Tesaro, Inc.

Metastatic cancers are the major reason for treatment failure in the clinic, but we lack a detailed understanding of how primary tumors metastasize, why these secondary tumors are relatively drug resistant, and what enables cancer cells to remain dormant and then cause disease relapse many years after apparently curative treatment. We are taking a multidisciplinary approach to attack these fundamental and related problems. Our major goal is to identify important cancer gene networks that are essential in human cancer progression, to guide the development and clinical use of new cancer drugs and diagnostics.... Read more about Sridhar Ramaswamy, MD

Pages